Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
CDE Annual Report: Clinical Trials for Innovative Drugs in China Reach Record High
The Center for Drug Evaluation (CDE) has released its annual report on clinical trials in...
Pfizer and Valneva’s Lyme Disease Vaccine VLA15 Shows Promise as Booster in Pediatric Trials
Partners Pfizer (NYSE: PFE) and Valneva SE (NASDAQ: VALN) have revealed that their Lyme disease...
European Commission Approves Pediatric Indication for MSD’s Ervebo Ebola Vaccine
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) approval for...
Cutia Therapeutics’ CU-40102 Meets Primary Endpoint in Phase III Study for Androgenic Alopecia
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its Phase III clinical study...
AstraZeneca’s Ultomiris Faces FDA Rejection for NMOSD Indication Extension
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has received a rejection from the US Food...
Chengdu Kanghua Receives FDA Approval for Clinical Trial of Norovirus Vaccine
China-based Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has announced that it has received...
Merck’s Keytruda Approved in China for MSI-H/dMMR Advanced Solid Tumors: A Biomarker-Driven Milestone
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its programmed...
Biocytogen Pharmaceuticals Enters Agreement with Myricx Bio for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody evaluation, option, and...
Danaher Partners with Beijing’s Changping District to Accelerate Science and Technology Innovation Center
US-headquartered Danaher (NYSE: DHR), a Fortune 500 science and technology innovator, has entered into a...
Chongqing Unveils Three-Year Public Health Action Plan Draft for Public Feedback
The health commission of Chongqing province has released the “Chongqing Public Health Capacity Improvement Three-year...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Pancreatic Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Shanghai Haihe Pharmaceutical’s Glumetinib Filed for Marketing in Japan for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd has announced the filing for marketing approval in Japan for...
Eminence Biotechnology Launches Fully Operational Cell Culture Media Facility in Suzhou
China-based Eminence Biotechnology (Suzhou) Co., Ltd. has announced the full operation of its state-of-the-art cell...
LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access
Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into...
Mindray Launches TE Air Wireless Handheld Ultrasound Solution in the US Market
China-based global device giant Mindray (SHE: 300760) has announced the market launch of its TE...
MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years
Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing,...
Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...